Schering Korea to launch Zevalin for NHL cancer.

Published: 2005-06-20 06:59:00

Updated: 2005-06-20 06:59:00

Schering Korea announced to launch Zevalin, a new drug for the treatment of non-Hodgkin's lymphoma, which was a rare cancer as widely known when the former first lady of the United States was struggling against. Zevalin is indicated for a slowly progressive follicle type of lymphoma as a first ra...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK